東北大学加齢医学研究所 臨床腫瘍学分野 東北大学 腫瘍内科

研究関係

HOME < 研究業績 < 英文論文 2019年度

英文論文 2019年度

  1. Abildgaard A B,Stein A,Nielsen S V,Schultz-Knudsen K,Papaleo E,Shrikhande A,Hoffmann E R,Bernstein I,Gerdes A M,Takahashi M,Ishioka C,Lindorff-Larsen K,Hartmann-Petersen R. Computational and cellular studies reveal structural destabilization and degradation of MLH1 variants in Lynch syndrome. Elife 8. Nov 7 (2019).
  2. Hamaguchi T,Denda T,Kudo T,Sugimoto N,Ura T,Yamazaki K,Fujii H,Kajiwara T,Nakajima T E,Takahashi S,Otsu S,Komatsu Y,Nagashima F,Moriwaki T,Esaki T,Sato T,Itabashi M,Oki E,Sasaki T,Chiron M,Yoshino T. Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. Cancer Sci 110. 3565-3572. Nov (2019).
  3. Kasahara Y,Shirota H,Umegaki S,Ishioka C. Contribution of Fcgamma receptor IIB to creating a suppressive tumor microenvironment in a mouse model. Cancer Immunol Immunother 68. 1769-1778.Nov (2019).
  4. Ikenoue T,Arai M,Ishioka C,Iwama T,Kaneko S,Matsubara N,Moriya Y,Nomizu T,Sugano K,Tamura K,Tomita N,Yoshida T,Sugihara K,Naruse H,Yamaguchi K,Nojima M,Nakamura Y,Furukawa Y. Importance of gastric cancer for the diagnosis and surveillance of Japanese Lynch syndrome patients. J Hum Genet 64. 1187–1194. Oct 7 (2019).
  5. Kato K,Cho B C,Takahashi M,Okada M,Lin C Y,Chin K,Kadowaki S,Ahn M J,Hamamoto Y,Doki Y,Yen C C,Kubota Y,Kim S B,Hsu C H,Holtved E,Xynos I,Kodani M,Kitagawa Y. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol Sep 27 (2019).
  6. Chikamatsu S,Saijo K,Imai H,Narita K,Kawamura Y,Katoh T,Ishioka C. In Vitro and in Vivo antitumor activity and the mechanism of siphonodictyal B in human colon cancer cells. Cancer Med 8. 5662-5672.Sep (2019).
  7. Imai H,Saijo K,Komine K,Otsuki Y,Ohuchi K,Sato Y,Okita A,Takahashi M,Takahashi S,Shirota H,Takahashi M,Ishioka C. Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study. Cancer Management and Research 2019:11. 7953–7965.Aug 22 (2019).
  8. Saijo K,Imai H,Ouchi K,Okada Y,Sato Y,Komine K,Takahashi M,Takahashi S,Shirota H,Takahashi M,Ishioka C. Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study. Tohoku J Exp Med 248. 37-43. May (2019).
  9. Yoshino Y,Qi H,Kanazawa R,Sugamata M,Suzuki K,Kobayashi A,Shindo K,Matsuzawa A,Shibata S,Endo S,Miyanishi Y,Shimaoka T,Ishioka C,Kanno S I,Yasui A,Chiba N. RACK1 regulates centriole duplication by controlling localization of BRCA1 to the centrosome in mammary tissue-derived cells. Oncogene 38. 3077-3092. Apr (2019).

ページの先頭へ戻る

© 2006 Department of Medical Oncology, Tohoku University Hospital All rights reserved.